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ABSTRACT
BACKGROUND Outcomes in patients with smaller body size after HeartMate 3 left ventricular assist device (HM3)
implantation are not well characterized. We sought to evaluate outcomes in smaller vs larger body surface area (BSA)
patients in the MOMENTUM 3 pivotal trial and its Continued Access Protocol cohort.
METHODS The analysis cohort included 1015 HM3 patients divided into 2 groups: BSA £1.70 m2 (small patients, n [
82) and BSA >1.70 m2 (large patients, n [ 933). The composite primary end point was survival at 2 years free of disabling
stroke or reoperation to replace or to remove a malfunctioning device. Adverse events were compared between groups.
RESULTS Smaller patients were more frequently women (56.1% vs 17.7%; P < .001) and had lower prevalence of
diabetes (28.1% vs 43.9%; P [ .005) and hypertension (51.2% vs 71.9%; P < .001), larger median indexed LVEDD
(normalized by BSA, 40 vs 33 mm/m2; P < .001), and lower median serum creatinine concentration (1.1 vs 1.3 mg/dL;
P < .001). The proportion of patients achieving the composite end point at 2 years was 77% in both groups (adjusted
hazard ratio, 1.14; 95% CI, 0.68-1.91; P [ .62). Two-year adverse event rates were also similar between groups except
for sepsis (6.1% vs 14.9%; P [ .029) and cardiac arrhythmias (24.4% vs 35.3%; P [ .005), which were higher in the
larger patients.
CONCLUSIONS Outcomes after HM3 implantation were comparable between small and large patients. Smaller body
size should not be used to deny HM3 implantation in patients who are otherwise suitable candidates for durable mechanical circulatory support.
(Ann Thorac Surg 2022;-:---)
ª 2022 by The Society of Thoracic Surgeons

D

urable mechanical circulatory support (MCS)

dramatic LVAD technology improvements. Large, pulsa-

devices have revolutionized the treatment of

tile devices have been replaced by miniaturized, intra-

end-stage heart failure during the last 25

pericardial, continuous ﬂow pumps, allowing use in

years. Small patients were initially deemed ineligible
for the bulky ﬁrst-generation volume displacement devices. The HeartMate XVE left ventricular assist device
(LVAD), for example, required a minimum body surface
area (BSA) of 1.5 m2. The MCS ﬁeld has since experienced

The Supplemental Material can be viewed in the online version of this
article [https://dx.doi.org/10.1016/j.athoracsur.2022.03.071] on http://
www.annalsthoracicsurgery.org.
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anatomic and physiologic concerns. For example, the
Abbreviations and Acronyms

perception that smaller patients have smaller left

BSA [ body surface area

ventricle (LV) size may affect their LVAD candidacy as

CAP [ Continued Access Protocol

it has been shown that patients with smaller LV cavities

HMII [ HeartMate II LVAD

have a differential outcome.2 Furthermore, small adult

HM3 [ HeartMate 3 LVAD
HR [ hazard ratio

patients have been signiﬁcantly underrepresented in

INTERMACS [ Interagency Registry for Mechanically Assisted

clinical trials and LVAD registries.3-11 Analyses from

Circulatory Support

The Society of Thoracic Surgeons Interagency Registry

IQR [ interquartile range

for Mechanically Assisted Circulatory Support (INTER-

LV [ left ventricle

MACS) database reported an average BSA of 2.07 m2 in

LVAD [ left ventricular assist device
LVEDD [ left ventricular end-diastolic diameter (i, indexed)

implanted patients7; however, only 2% of patients had

MCS [ mechanical circulatory support

a BSA 1.5 m2.9 In addition to anatomy, clinician con-

QOL [ quality of life

cerns include a potential higher incidence of adverse
events, such as stroke, pump thrombosis, infection,

smaller adults and more recently in pediatric patients.1

bleeding, and right ventricle failure,9,12,13 and a percep-

However, the safety and efﬁcacy of LVADs in small pa-

tion that LVADs cause more pain in small patients.

tients have been understudied, and small adults are still

The HeartMate 3 LVAD (HM3) is a fully magnetically

frequently denied durable LVAD therapy on the basis of

levitated, intrapericardial pump with a short inlet cannula (Abbott).14 This pump demonstrated superior results compared with the HeartMate II LVAD (HMII;

TABLE 1

Abbott), which required a preperitoneal pump pocket

Baseline Demographics and Preoperative Characteristics

and was not designed for small patients.15 Despite the
Demographic

BSA, m

2

BSA 1.70 m2
(n ¼ 82)

BSA >1.70 m2
(n ¼ 933)

1.63 (1.54-1.68)

2.08 (1.92-2.26)

P valuea

<.001

successful use of HM3 in the general population of LVAD
patients, there remains a lack of HM3 clinical data speciﬁc to small patients.

BMI, kg/m2

21 (19-24)

29 (25-33)

<.001

Age, y

64 (53-70)

62 (53-69)

.38

Female

46 (56.1)

165 (17.7)

White

48 (58.5)

627 (67.4)

Access Protocol (CAP) study. We hypothesized that

Black

23 (28.1)

262 (28.1)

Asian/Paciﬁc Islander

7 (8.5)

9 (1.0)

“small” HM3 patients (BSA 1.70 m2) have similar

Other race

4 (4.9)

33 (3.5)

Destination therapy

58 (70.7)

569 (61.0)

Ischemic cause of heart failure

27 (32.9)

408 (43.7)

.06

History of diabetes

23 (28.1)

410 (43.9)

.005

History of hypertension

42 (51.2)

671 (71.9)

<.001
0.11

Race

History of ICD insertion

51 (62.2)

659 (70.6)

IABP

14 (17.1)

129 (13.8)

INTERMACS proﬁle
1

uated outcomes of small patients who received the HM3

<.001

within the MOMENTUM 3 pivotal trial and its Continued

overall outcomes compared with “large” HM3 patients
.08

.42
.69

0 (0)

In this nonpowered, retrospective analysis, we eval-

<.001

with (BSA >1.70 m2).

PATIENTS AND METHODS
PATIENT COHORT. The analysis cohort includes 515 pa-

tients implanted with HM3 in the MOMENTUM 3 pivotal
trial (NCT02224755) and the ﬁrst 500 of 1685 patients

22 (2.4)

2

25 (30.5)

274 (29.6)

implanted

3

45 (54.9)

495 (53.5)

(NCT02892955). Patients were observed for 2 years with

in

the

MOMENTUM

3

CAP

cohort

4-7

12 (14.6)

135 (14.6)

a data cutoff in February 2020. The MOMENTUM 3

63 (58-70)

68 (62-76)

<.001

2

LVEDDi, mm/m

40 (36-43)

33 (29-37)

<.001

Mean arterial pressure, mm Hg

73 (69-82)

79 (73-87)

<.001

Pulmonary capillary wedge pressure, mm Hg

22 (14-28)

24 (17-29)

.06

8 (4-13)

10 (6-15)

.009

continued evaluation of the HM3. Both studies were

LVEDD, mm

Central venous pressure, mm Hg

pivotal trial was a multicenter, randomized study
comparing the HM3 with the HMII.16 MOMENTUM 3 CAP
is a single-arm, prospective, multicenter study for

Pulmonary vascular resistance, Wood units

3.4 (2.2-4.5)

2.8 (1.9-4.1)

.04

sponsored by Abbott. Protocols were approved by each

Total bilirubin, mg/dL

0.8 (0.6-1.3)

0.9 (0.6-1.3)

.61

Institutional Review Board, and written informed

Blood urea nitrogen, mg/dL

23 (18-29)

25 (19-35)

.036

consent was obtained from all patients or their

Albumin, g/dL

3.6 (3.2-3.8)

3.6 (3.3-3.9)

.32

1.1 (0.9-1.4)

1.3 (1.0-1.6)

<.001

authorized representatives.

Creatinine, mg/dL

a
Wilcoxon rank sum test or c2 or Fisher exact test as appropriate. Continuous variables are presented as
median (interquartile range). Categorical variables are presented as counts (percentage). BMI, body mass
index; BSA, body surface area; IABP, intra-aortic balloon pump; ICD, implantable cardioverter-deﬁbrillator;
INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LVEDD, left ventricular enddiastolic diameter; LVEDDi, indexed LVEDD.

DEFINITION OF SMALL BSA. No consensus for small body

size deﬁnition exists for adult LVAD recipients. Patients
with BSA 1.2 m2 were eligible for LVAD implantation in
MOMENTUM 3 and CAP. Only 14 analysis cohort patients
(1.4%) had BSA 1.50 m2. For our analysis, the threshold
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for small BSA was set at the 10th percentile (rounded

in Supplemental Tables 1 and 2. Adverse event rates

down to the nearest tenth) of the available patient dis-

are shown as percentage of patients experiencing

tribution (BSA 1.70 m2).

events and events per patient-year compared between

END POINTS. We analyzed pump parameters, left ven-

tricular end-diastolic diameter (LVEDD), and the index
parameter of LVEDD normalized by BSA (LVEDDi)
between

groups.

The

MOMENTUM

3

composite

primary end point, survival at 2 years free of disabling
stroke (modiﬁed Rankin score >3) or reoperation to
replace or to remove a malfunctioning pump, was
evaluated. Death, disabling stroke, pump exchange,
explantation for reason other than myocardial recovery,

groups using Poisson regression. Rate differences are
described as rate ratios and 95% CIs. Longitudinal
changes in LV size, pump parameters, 6-minute walk
test distance, and QOL were analyzed by repeated
measures linear mixed effects modeling.
All reported P values are 2 tailed, and P values < .05
are considered statistically signiﬁcant. Statistical analyses were performed with SAS software, version 9.4
(SAS Institute).

urgent transplantation for device malfunction, and
withdrawal from the study were considered failures of

RESULTS

the primary end point. Other end points included
CHARACTERISTICS. The

analysis

cohort

overall survival, adverse events, functional status and

BASELINE

quality of life (QOL) by New York Heart Association

included 1015 HM3 patients with average BSA of 2.07 

class, 6-minute walk distance, and EuroQol 5-Dimension

0.27 m2. There were 82 small patients (1.70 m2) and 933

5-Level (EQ-5D-5L) visual analog scale over time.

large patients (>1.70 m2). Small patients were charac-

Moderate to extreme pain or discomfort as reported by

terized by lower baseline blood urea nitrogen and

the

creatinine

patient

in

the

EQ-5D-5L

Finally,

we

questionnaire

was

concentrations

but

higher

pulmonary

whether

vascular resistance. They were also more likely to be

readmission rates due to low ﬂow alarms were higher in

female or of Asian descent and were less likely to have a

small patients.

history of diabetes or hypertension compared with larger

investigated.

examined

patients (Table 1).
STATISTICAL ANALYSIS. Continuous variables are pre-

In comparison to larger patients, the small patients

sented as median and interquartile range (IQR) or mean

had lower baseline LVEDD but higher LVEDDi. Figure 1

 standard deviation. Categorical variables are described

shows the relationship between LVEDD and LVEDDi vs

as counts and percentages. Univariate comparisons of

BSA. Outcomes for patients stratiﬁed by LVEDD are

median values were performed with Wilcoxon rank sum

provided for reference in Supplemental Figure 1.

test. Univariate comparisons of categorical variables
were performed with c2 test or Fisher exact test as

INTRAOPERATIVE

appropriate. The Kaplan-Meier method was used to

RESULTS. In smaller vs larger patients, median implant

calculate survival estimates for time-to event analyses.

time (260 [IQR, 198-340] minutes vs 264 [IQR, 205-343]

Cox

AND

EARLY

POSTOPERATIVE

models

were

used

to

minutes; P ¼ .97), cardiopulmonary bypass time (83

ratios

(HRs)

for

the

[IQR, 64-107] minutes vs 83 [IQR, 64-110] minutes;

composite primary end point and survival as described

P¼.97), and need for concomitant procedures (36.6% vs

proportional

calculate

adjusted

hazards
hazard

FIGURE 1 Scatter plots demonstrating the relationship between left ventricular end-diastolic diameter (LVEDD) vs body
surface area (BSA) and LVEDD normalized by BSA (LVEDDi) vs BSA. The red and blue dots represent patients with BSA
£1 . 7 0 m 2 a n d B S A > 1 . 7 0 m 2 , r e s p e c t i v e l y , a n d d e m o n s t r a t e t h a t s m a l l e r b o d y s i z e d o e s n o t e q u a t e t o s m a l l e r L V E D D .
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indexed ﬂows (ﬂow normalized by BSA) were higher in
smaller patients (P < .05). Compared with large patients,
LVEDD in small patients continued to be lower with
LVAD support but LVEDDi was higher (Supplemental
Figure 2). Mean arterial pressure averages were not
signiﬁcantly

different

between

groups

over

time

(Supplemental Table 4).
PRIMARY COMPOSITE END POINT AND SURVIVAL. Kaplan-

Meier estimates for the composite end point of survival
free of disabling stroke or reoperation to replace a malfunctioning pump are shown in Figure 2A. The proportion of patients achieving the composite end point at 2
years was 77.0% in both groups (adjusted HR, 1.14; 95%
CI, 0.68-1.91; P ¼ .62). In Supplemental Figure 3, KaplanMeier estimates of the composite primary end point in
additional substratiﬁcations of BSA ranges (1.50 m2,
1.51-1.70 m2, 1.71-2.00 m2, 2.01-2.30 m2, and >2.30 m2)
were also similar (log-rank, P ¼ .97).
Kaplan-Meier estimates of overall survival at 2 years
were 82.6% and 81.2% in small and large patients,
respectively (adjusted HR, 1.13; 95% CI, 0.64-2.01; P ¼
.67; Figure 2B). Causes of death for both groups are reported in Supplemental Tables 5 and 6. Competing
outcomes for both cohorts are shown in Supplemental
Figure 4.
ADVERSE EVENTS. The 2-year adverse event incidence

and rates are shown in Table 2. There were no
signiﬁcant differences except for lower incidences of
sepsis,

cardiac

arrhythmias,

and

ventricular

arrhythmias in small patients. There was numerically
but not statistically signiﬁcantly more right ventricular
FIGURE 2 (A) Kaplan-Meier estimates of the composite primary

assist device use in small patients (8.5% vs 5.1%; P ¼ .19).

end point, survival free of disabling stroke or reoperation to replace
a malfunctioning pump, in patients with body surface area (BSA)
£1 . 7 0 m 2 a n d B S A > 1 . 7 0 m 2 w h o u n d e r w e n t H e a r t M a t e 3

FUNCTIONAL STATUS AND QOL

implantation. (B) Kaplan-Meier estimates of overall survival in
s m a l l e r a n d l a r g e r B S A p a t i e n t s . B S A £1 . 7 0 m 2 w a s n o t a s s o c i a t e d

Both groups experienced similar heart failure symptom

with increased risk of composite end point failure or mortality. Error

improvements (Figure 3A) and signiﬁcant increases in

bars denote 95% CIs for Kaplan-Meier estimates. *Hazard ratio (HR)
is adjusted for age, ischemic heart failure, pulmonary vascular
resistance, and blood urea nitrogen level.

6-minute walk test distances from baseline (Figure 3B).
The cohort of small patients had slightly better QOL
during the 2-year follow-up (P ¼ .037; Figure 4), and
the degree of moderate to extreme pain or discomfort

36.4%; P¼.98) were comparable. The rate of discharge
on HM3 support from implant hospitalization was

was

no

different

between

groups

(Supplemental

Figure 5).

similar between groups (92.7% vs 94.9%; P¼.40), but

READMISSIONS ASSOCIATED WITH LOW FLOW ALARMS. Of

median length of stay was longer for smaller patients (21

the patients discharged from the implant hospitaliza-

[IQR, 17-29] days vs 19 [IQR, 14-25] days; P ¼ .032).

tion, 22.4% of small and 14.2% of large patients were
later readmitted for low ﬂow alarms (P ¼ .06), detailed in

PUMP PARAMETERS, CHANGES IN LVEDDI, AND
MEAN ARTERIAL PRESSURE
Average HM3 pump speeds and estimated ﬂows at

Supplemental Table 7.

COMMENT

different time points are shown in Supplemental Table 3.

In this study, we report the baseline characteristics and

At all time points, small patients were supported at

clinical outcomes of small (BSA 1.70 m2) compared

lower pump speeds and ﬂows over time. However,

with large HM3 patients enrolled in the MOMENTUM 3
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FIGURE 3 Functional status over time as measured by (A) New York Heart Association (NYHA) classiﬁcation and (B) 6m i n u t e w a l k d i s t a n c e ( 6 M W D ) i n p a t i e n t s w i t h b o d y s u r f a c e a r e a ( B S A ) £1 . 7 0 m 2 a n d B S A > 1 . 7 0 m 2 . B o t h g r o u p s
demonstrated improvements from baseline. *P < .05 for smaller vs larger BSA at the study time point by c2 test.

pivotal trial and CAP cohort. We found that small adult

Although it is unclear whether ventricular size plays a

HM3 patients are more likely to be female, to have lower

signiﬁcant role in determining LVAD outcomes, at least 2

incidence of diabetes and hypertension, to have rela-

studies have shown potential importance. In a cohort of

tively large LVs, to have lower pump speeds but higher

HMII recipients, an LVEDD smaller than 60 mm was

indexed ﬂows, to achieve similar 2-year survival as large

associated with higher risk of stroke and mortality.19 In

patients, to demonstrate a favorable adverse event pro-

an INTERMACS analysis, Shah and colleagues20 found

ﬁle including low rates of stroke and pump thrombosis,

that survival improved with progressive increase in LV

and to show comparable improvements in functional

size. An important ﬁnding of this study is that small

status and QOL.

body size does not equate to small LV size. Analysis of

The association between female sex and smaller body

LVEDD normalized by BSA may be an informative index.

size in durable LVAD recipients has been previously

According to the American Society of Echocardiography

demonstrated.,9,10,13,17,18

speciﬁc

and the European Association of Cardiovascular Imag-

phenotype for this underserved population of patients

ing, normal LVEDDi ranges are 22 to 30 mm/m2 for men

has not been well characterized. As expected, smaller

and 23 to 31 mm/m2 for women.21 In our study, we found

BSA patients in our analysis have high female repre-

that LVEDDi was abnormally high in both groups.

sentation and a lower body mass index. This smaller size

Furthermore, LVEDDi was higher in smaller patients and

cohort of patients also demonstrated lower incidence of

remained higher throughout the follow-up period.

diabetes and hypertension. INTERMACS proﬁles and

Although preimplantation LVEDD may represent a more

implant strategy were comparable between groups, but

important variable than BSA in many patients, we did

there was a tendency toward use as destination therapy

not ﬁnd differences in failure of the primary composite

for the smaller patients (70.7% vs 61.0%).

end point between patients with different LVEDD

However,

a

more
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TAB LE 2

Adverse Events at 2 Years

Adverse event

Suspected device thrombosis
Stroke
Disabling (MRS >3)
Bleeding
Gastrointestinal
Major infection
Driveline
Sepsis
Right-sided heart failure
RVAD or inotropes ‡14 days
RVAD
Cardiac arrhythmia
Ventricular
Renal dysfunction

EPPY

BSA 1.70 m2 (n ¼ 82)
No. (%)

BSA >1.70 m2 (n ¼ 933)
No. (%)

P valuea

BSA 1.70 m2

BSA> 1.70 m2

Rate ratio (95% CI)

1 (1.2)

13 (1.4)

1.00

0.01

0.01

0.87 (0.11-6.65)

.89

11 (13.4)

95 (10.2)

.36

0.10

0.08

1.26 (0.69-2.28)

.45

P valueb

5 (6.1)

44 (4.7)

.58

0.04

0.04

1.13 (0.45-2.84)

.79

37 (45.1)

427 (45.8)

.91

0.76

0.66

1.16 (0.94-1.43)

.17

19 (23.2)

243 (26.1)

.57

0.35

0.34

1.02 (0.75-1.40)

.89

45 (54.9)

528 (56.6)

.76

0.78

0.77

1.01 (0.82-1.24)

.92

24 (29.3)

218 (23.4)

.23

0.27

0.22

1.26 (0.88-1.80)

.20
.014

5 (6.1)

139 (14.9)

.029

0.04

0.12

0.33 (0.13-0.80)

25 (30.5)

319 (34.2)

.50

0.22

0.26

0.87 (0.59-1.27)

.47

19 (23.2)

171 (18.3)

.28

0.15

0.13

1.17 (0.73-1.87)

.52

7 (8.5)

48 (5.1)

.19

0.06

0.03

1.62 (0.73-3.57)

.24

20 (24.4)

329 (35.3)

.047

0.18

0.35

0.50 (0.33-0.77)

.002

8 (9.8)

195 (20.9)

.016

0.07

0.21

0.35 (0.18-0.68)

.002

7 (8.5)

132 (14.2)

.16

0.06

0.11

0.52 (0.24-1.11)

.09

a
The c2 test or Fisher exact test as appropriate; bPoisson regression. Boldface P values represent statistical signiﬁcance. BSA, body surface area; EPPY, events per patient-year; MRS, modiﬁed Rankin
score; RVAD, right ventricular assist device.

ranges, including patients with LVEDD smaller than 50

described to date. In this study, intraoperative ﬁndings

mm. However, evaluation of the inﬂuence of LV size on

were comparable between the groups with similar pro-

outcomes was limited by the low number of patients

cedure length, cardiopulmonary bypass time, and inci-

with a small LVEDD in our study. A larger population of

dence of concomitant procedures. Smaller patients were

patients from large registries with more heterogeneous

managed with lower pump speeds throughout follow-up

LVEDD is necessary to investigate the inﬂuence of a

and achieved lower pump ﬂows compared with larger

small LV cavity in LVAD outcomes. The relationships

patients, which is indicative of allometric relationship

between body size, ventricular size, and clinical out-

between body size and cardiac output. However, the

comes play an important role in patient selection and

indexed pump ﬂows were higher in the group of smaller

warrant further study.

patients, whereas mean arterial pressure was main-

Tailoring speciﬁc surgical implantation techniques to

tained at similar levels compared with the larger pa-

small patients may be necessary but has not been

tients. As mean arterial pressure was not found to

FIGURE 4 Quality of life over time as measured by the EuroQol 5-Dimension 5-Level (EQ-5D-5L) visual analog scale in
p a t i e n t s w i t h b o d y s u r f a c e a r e a ( B S A ) £1 . 7 0 m 2 a n d B S A > 1 . 7 0 m 2 . B o t h g r o u p s d e m o n s t r a t e d s i g n i ﬁ c a n t i m p r o v e m e n t s
from baseline. Overall, the smaller BSA cohort also had slightly better scores during the 2-year follow-up compared with
larger patients (P [ .037).
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correlate with body size, this may suggest the presence

alarm threshold compared with larger patients. Native

of lower systemic vascular resistance index in smaller

heart contribution to the cardiac output through the

patients as well.

aortic valve was not measured in the MOMENTUM 3

A main ﬁnding of our study is that survival free of

trial; therefore, we cannot conclusively explain these

disabling stroke and pump replacement and overall

ﬁndings. Additional studies investigating the long-term

survival were similar between groups. A 2017 INTER-

safety of patients supported with lower pump ﬂows

MACS analysis showed similar overall survival between

are needed.

patients with BSA 1.5 m2 and BSA >1.5 m2.9 A multi-

Finally, small patients enjoyed similar improvements

center Japanese study also reported similar survival

in functional status and QOL compared with larger pa-

outcomes in 30 patients with BSA <1.5 m2 compared

tients. As LVAD technology evolves and patients expe-

with 74 patients with BSA 1.5 m2 who received the

rience longer survival, improvements in these areas

HMII.13

become increasingly important. Pain and discomfort

Few studies have investigated whether small patients

were not more common in the smaller patients, reas-

experience a different adverse event proﬁle. Zafar and

suring because of a risk of more physical interactions

coworkers9 reported higher incidence of bleeding and

between the device and the chest wall, a potential

driveline infections and lower rates of late right-sided

source of pain.

heart failure and renal dysfunction in patients with
BSA 1.5 m2. Ono and colleagues13 also found a higher

LIMITATIONS. This analysis has several key limitations.

incidence of driveline infections in this population of

First, this was a nonpowered, retrospective evaluation of

small patients. A European study that investigated out-

MOMENTUM 3 pivotal trial and CAP patients. The entry

comes in 167 patients who received the Berlin Heart

criteria restricted patients to BSA 1.2 m2. Second, our

2

INCOR LVAD demonstrated that BSA <1.87 m was an

cutoff of BSA 1.70 m2 was chosen to achieve a sufﬁ-

independent risk factor for death due to stroke or sys-

ciently large sample that nevertheless represents the

temic bleeding.12 In general, results from our analysis

extreme low end of the size distribution (<10th

demonstrate similar adverse event rates between

percentile). Most of our small patients had a BSA be-

smaller and larger HM3 patients. It is reassuring that

tween 1.50 and 1.70 m2, and therefore our results mainly

despite the lower pump speeds and lower ﬂows

apply to patients in this more limited BSA range. Con-

demonstrated in smaller patients, the incidence of pump

ducting the main comparative analysis with the histori-

thrombosis and stroke was similar, perhaps because

cal cutoff BSA 1.50 m2 was not possible because only 14

of full magnetic levitation technology, which has

patients would have qualiﬁed. However, a supplemental

been associated with a lower incidence of hemo-

analysis of the group with BSA 1.50 m2 showed similar

compatibility adverse events.

16,22

Driveline infections

results to larger patients with respect to the primary end

were comparable between groups. A lower incidence of

point at 2 years. It is possible that the observed out-

ventricular arrhythmias was seen in smaller patients.

comes may have differed if more patients with BSA

Although this ﬁnding may be counterintuitive, it sug-

1.50 m2 had been enrolled. Also, with only 82 patients

gests that potential contact between the inﬂow cannula

in the group with BSA 1.70 m2, the analyses are still

and the myocardial wall in smaller patients may no

somewhat underpowered and at risk of type II error.

longer be a concern. It is possible that the higher inci-

Despite these limitations, our study provides important

dence of ventricular arrhythmias in larger BSA patients

long-term clinical evidence in a group of smaller patients

in this study is related to a larger body size,23 a larger

who constitute a minority of the overall population of

preoperative LV size,24 and a more frequent history of

LVAD patients but may beneﬁt from HM3 therapy.

implantable cardioverter-deﬁbrillator insertion. Rightsided heart failure is a complication believed to poten-

CONCLUSION. Small body size (BSA 1.70 m2) should not

tially affect smaller patients more than larger patients. In

represent an exclusion criterion for HM3 implantation in

our analysis, right ventricle failure rates were similar

patients with advanced heart failure who are otherwise

between groups, but there was a numerically higher rate

candidates for durable MCS and exhibit a dilated LV. The

of right ventricular assist device use in smaller patients.

relationship between body size, ventricle size, and

An interesting ﬁnding of this study is that despite
demonstrating higher indexed pump ﬂows (normalized

postimplantation

outcomes

deserves

further

investigation.

by BSA), readmissions secondary to low ﬂow alarms
were numerically higher in the smaller BSA group.
However, low ﬂow alarms are triggered by absolute
pump ﬂows (2.5 L/min), not indexed ﬂows. It is possible
that conditions such as dehydration and hypertension
more frequently expose smaller patients to the low ﬂow
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